A gain-of-function mutation of JAK2 in myeloproliferative disorders - sprookjes - yvandenbroek - TriplyDB

A gain-of-function mutation of JAK2 in myeloproliferative disorders

A gain-of-function mutation of JAK2 in myeloproliferative disorders

http://www.wikidata.org/entity/Q29618851

about

Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans Essential thrombocythemia Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin Janus kinases in immune cell signaling The molecular mechanisms that control thrombopoiesis Platelet genomics and proteomics in human health and disease.Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis Venous thromboembolic disease Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy Mast cell homeostasis and the JAK-STAT pathway Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray Selectivity and therapeutic inhibition of kinases: to be or not to be?Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders Therapeutic targeting of Janus kinases The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo Recent advances in understanding myelofibrosis and essential thrombocythemia Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis Genomic landscape of megakaryopoiesis and platelet function defects Personalized medicine in gastric cancer: Where are we and where are we going?Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Chronic neutrophilic leukemia: a clinical perspective JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F New Therapeutic Approaches in Polycythemia Vera Clinical potential of pacritinib in the treatment of myelofibrosis Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms Genetics of myeloproliferative neoplasms

P2860

5451e0461985a93a4a280b6d5ca2ce151d2ed868

P248

Q21133609-7D45CB44-94C8-4920-AAAE-BEAC6B00308B Q21202968-ADE86AE3-ADC0-4D25-87EC-A2FA9D4F15BA Q24297854-AB218C74-5BF7-42D9-81DD-C52CF31E16BE Q24318979-C2DAE6FD-C70F-4803-951E-893C3BDE2EE7 Q24322021-DC2A9049-9606-4BAC-9B32-0470451BD146 Q24536138-D75D8D80-3633-4E7A-8B73-A57CCE83B12B Q24536151-62B66D7F-6003-4C4C-81B8-A1F5A7F00DD7 Q24568313-D7163DD1-9150-45A2-BAEF-8A837BEB30A2 Q24609999-2EF3EEE1-2DD7-426F-9873-B20E86C4E585 Q24631121-918DBE07-E776-48FA-B046-A5771205A902 Q24631288-6BD091A5-E47E-44F8-AFF5-BAF4A6277600 Q24632515-320E9B37-DD74-4E9F-A5C1-528B6F655115 Q24645177-58C8796B-EF16-4978-A5CA-3ED0124093E7 Q24648438-91F06D13-FAEC-4097-A30D-07E75F7194AC Q24650855-8A774617-6586-4CF2-AE6A-B3F3B5DA426D Q24656006-13B24AFF-275D-43A9-87DC-925FECB4C1C1 Q24657681-CAE5536C-D83A-40F7-9457-1D24DE3FF178 Q24658483-909E300E-B60E-45B1-9BFA-2629A484EF38 Q24675681-7D82DCDB-BDB7-48BC-ADED-D2EE0214434C Q24676526-C66E7512-A10D-4312-80C6-6CB01128B00F Q24676798-6871D492-4A30-49A7-88F5-0FDA43AEE977 Q24685447-3824A3D6-6452-4FB6-972E-E2B87442B559 Q24685474-DD23A637-52C2-4502-9779-6FEB9F8E23D5 Q24685620-1085F0CF-902B-4962-AE76-C1932C458E39 Q26748543-86DD35DD-74AD-4BEA-87F9-4C0827E19E7A Q26750696-06E9E0F4-66F1-4F2D-9316-80043872AECF Q26766319-9D6089C9-47E5-4EF9-BCB0-101A59EA3307 Q26770330-677C2322-3110-4156-B9B3-DD107E552AF2 Q26770869-E87A0CD4-99EA-4832-BEFD-8CED1940ACC8 Q26774521-D7843EBD-E01B-4706-BDCA-B0ABA80639C6 Q26777265-B4407D4D-590A-48BD-B80F-7146E684809B Q26778929-E5E4F5E4-7552-407A-9179-56B6B146D6C0 Q26779960-D4FD9C0D-0897-4F4B-9F12-A4AF9429F924 Q26781167-508A86DE-BFAD-4457-9968-4558864E7B9D Q26782539-655A6171-EDEE-4D15-BBF5-3FAE341D9CCB Q26795666-90661A81-91EF-4C03-8FC3-89AD04C94AAA Q26795677-750446FB-C23E-415F-9FD3-F9C0AF318187 Q26796450-4E6B0ADB-3130-4D91-9B4C-5A37785841E1 Q26799790-2347F00A-D3B4-4A39-9D1B-3076FDD66714 Q26823651-361904A5-B366-403A-BBD2-D1DDF3A22A4F

P2860

A gain-of-function mutation of JAK2 in myeloproliferative disorders

http://www.wikidata.org/entity/Q29618851

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@ast

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@en

type

label

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@ast

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@en

prefLabel

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@ast

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@en

P1433

Q29618851-5BF44C54-59E7-4651-AE07-9E940B620D7D

P1476

Q29618851-4FFC0F88-9E4E-42DD-B816-928C1B2E2572

P2093

Q29618851-0DBE9A5B-FEDB-42F2-816B-CF87C1D0F689

Q29618851-5CB1A5A8-F487-46ED-A638-0E4E3BF58120

Q29618851-93F34F96-3FA0-403B-8FFD-45211BB142D2

Q29618851-B953B99E-8CB2-4070-BF4A-E3990758AFFB

Q29618851-D90A525A-7285-4A42-9FF0-4467E30A7046

Q29618851-EA130071-EFA3-4D31-85B9-25EF582CEA8D

P304

Q29618851-EEDE7A1A-5D41-4E2D-8869-789C502FA667

P31

Q29618851-72C92CD7-3531-46AF-9A9D-86521554386A

P3181

Q29618851-64409249-2016-4915-9A1E-959BE937587C

P356

Q29618851-912C2635-9B3A-4A56-9359-5703EB864943

P407

Q29618851-094A2666-6DAB-482B-B55A-20EB3BCEC47F

P433

Q29618851-F8E9BC9E-EBBD-4741-9FEF-CDAC51F75567

P478

Q29618851-670B9589-ADDB-4A03-BB24-38317492C4C4

P50

Q29618851-0F727F49-2B00-4BD0-B1E7-A1460DD516A4

Q29618851-4660924E-D952-4253-AB6E-33E0E39CFBAC

Q29618851-AB4DC915-6A32-4B7F-B3EA-D4AD63FB6FC1

P577

Q29618851-9326FF81-7CD3-4B6F-A2C6-EF8262B4817A

P698

Q29618851-AB7F32AF-71EC-4D5F-90E0-F92D05627C16

P3181

P356

P1433

The New England Journal of Medicine

P1476

A gain-of-function mutation of JAK2 in myeloproliferative disorders

@en

P2093

Andre Tichelli

http://www.w3.org/2001/XMLSchema#string

Andreas S Buser

http://www.w3.org/2001/XMLSchema#string

Mario Cazzola

http://www.w3.org/2001/XMLSchema#string

Radek C Skoda

http://www.w3.org/2001/XMLSchema#string

Ralph Tiedt

http://www.w3.org/2001/XMLSchema#string

Soon-Siong Teo

http://www.w3.org/2001/XMLSchema#string

P304

1779-1790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1425128

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA051113

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

352

http://www.w3.org/2001/XMLSchema#string

P50

Robert Kralovics

Francesco Passamonti

Jakob R. Passweg

P577

2005-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15858187

http://www.w3.org/2001/XMLSchema#string